Loading...
Market
Will AstraZeneca's stock price increase by more than 10% by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news sources
Story
AstraZeneca Overturns $107.5 Million Verdict in Patent Dispute with Pfizer
Aug 14, 2024, 07:00 PM
AstraZeneca has successfully overturned a jury verdict that required the company to pay $107.5 million for infringing cancer-drug patents owned by Wyeth, a subsidiary of Pfizer. The decision was made by a federal judge in Delaware, marking a significant legal victory for AstraZeneca. Pfizer, which acquired Wyeth in 2009, initially filed the lawsuit against AstraZeneca in 2021. This outcome is seen as a milestone decision for UK companies, particularly for AstraZeneca's CEO Pascal Soriot and the shareholders who supported his vision.
View original story
Similar markets
Yes • 50%
No • 50%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Yes • 50%
No • 50%
